Ajinomoto says its flexible approach to tech licensing differs from rivals who are more focused on locking customers into manufacturing services contracts.
Agricultural technology firm Monsanto has partnered with Complix NV to develop the latter’s protein therapeutic targeting technology for crop protection applications.
A new simplified analysis technique of the binding kinetics of membrane proteins could solve a host of drug delivery problems, according to scientists from the Arizona State University.
A new non-glycosolated protein production method using E.coli can cut manufacturing costs by up to 50 per cent as well as speeding up the process, according to researchers at the University of Arkansas.
A new hydrogel which can provide a sustained drug release of up to six months could cut diabetes dosage down from 365 injection per year to just two, according to researchers.
Drug regulators and the biomanufacturing industry need to embrace drug delivery via the skin to solve solubility problems with peptides and proteins, according to Across Barriers’ Udo Bock.
RNA therapeutics developer Arrowhead Research has bought Alvos Therapeutics in the hope that peptide targeting technology will help it overcome delivery challenges.
Custom antibody manufacturer Cambridge Research Biochemicals (CRB) has expanded its range of labelling dyes through a new agreement with supplier Life Technologies.
AIT Bioscience says its new alliance with Perfinity Biosciences will provide protein analysis in 10 minutes, rather than the 48 hours that is standard across the industry.
Tissue-based delivery tech developer Medgenics is in talks with Baxter Healthcare about new deal, but says continued focus on Factor VIII is not ‘mission critical’ to biopump platform.
Costly and time consuming drug screening could soon be a thing of the past thanks to new easy-bake synthetic cell membranes made at the Institute of Materials Research and Engineering (IMRE).
ProJect Pharmaceutics has opened its Munich headquarters and laboratory facilities in Martinsreid, Germany, beginning business operations to transform proteins, peptides and small molecules into novel drugs.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
Reengineering erythropoietin (EPO) as an immunoglobulin G (IgG) fusion protein enables penetration of the blood-brain barrier (BBB) in mice, according to researchers.
Cell penetration and pharmacodynamics boosting “stapled peptide” tech wins Aileron Therapeutics potential billion dollar protein drug development deal with Roche.
CardioGenics predicts yield boosting “biologics beads” will change the antibody extraction landscape after signing distribution deal with Merck Chimie.
Roche has licensed Aegis Therapeutics’ ProTek stabilisation technology, which uses GRAS excipients to prevent aggregation and therefore improve production of peptide and protein drugs.
PX'Therapeutics SA, formerly called Protein'eXpert, has set up an additional biomanufacturing unit dedicated to producing therapeutic proteins and monoclonal antibodies in mammalian cells.
Coupling interferon to a synthetic PEG molecule could increase the therapeutic’s dosing schedule from every other day to every one to two weeks, according to researchers who believe the technology has blockbuster potential.
Researchers have used nanoparticles to stabilise membrane proteins, allowing for detailed analysis of their structure and molecular functions that could help drug discovery.
Emisphere has entered into a research agreement with Syracuse University, which will combine their respective oral drug delivery technologies to enhance absorption of an appetite-suppressing hormone.
Millipore has launched its single-use ChromaSorb membrane adsorber, which binds negative impurities from host cell protein (HCP), DNA, endotoxins, and viruses at high salt concentrations.
Pfizer has outlined its post-Wyeth takeover operating structure, which it believes will ensure the mega-merger boosts R&D and create the “world's premier biopharmaceutical” company.
Ion channel expert ChanTest is expanding its range of ion channel services and cell lines that help identify promising target compounds and those that could cause harmful side effects.
European researchers have devised a method of purifying parasites that will enable scientists to gain deeper insights into the biology of the organisms responsible for millions of infections every year.
Hungarian researchers have developed a new bioinformatics tool that can identify and correct abnormal, incorrect and mispredicted protein annotations in public databases.
US researchers have developed a new technique that has enabled them to determine the structure of membrane proteins without having to first crystallise the samples.
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.
Bio-Rad has published several application notes describing the use of its Profinity eXact protein expression system to obtain tag-free native proteins from a cell lysate in less than an hour.
Thermo Fisher Scientific has followed up its acquisition of Open Biosystems with the purchase of antibody experts Affinity BioReagents to further bolster its protein research offering.
The PER.C6 cell culture-based antibody production platform has
achieved a new record yield of 27 grams of IgG antibody per litre,
bettering the 15 gram per litre mark that was reported earlier in
the year.
Denmark's Novozymes has signed an exclusive worldwide licensing
agreement with CSL Behring for albufuse, a proprietary albumin
fusion technology that can extend the circulatory half-life of
therapeutic proteins through genetic...
Redpoint Bio has been issued with a patent for an assay technology
which tests whether a compound enhances or inhibits the bitter or
sweet taste of different ingredients, allowing the company to
screen for flavour enchancing compounds.
Plexera Biosciences is hoping to leave its rivals in its wake
following an exclusive option agreement for Auguron Biosciences'
DNA-based protein chips.
France-based Flamel Technologies and Merck Serono have shook hands
on a new €2m ($2.9m) deal which would see Flamel's Medusa
technology used to develop an extended-release profile of an
undisclosed therapeutic protein.
Medgenics' Biopump could be the solution to the issues surrounding
protein therapy and is set to take on the $51bn US
biopharmaceutical market after raising £3.28m ($6.76m) in funding
in its Initial Public Offering.
Researchers from Amgen have published results detailing a method
that improves the analysis of the sugar groups attached to
monoclonal antibodies (MAbs) and proteins.
Scientists have discovered how neurons keep themselves sugar-free
and healthy, a process that must be upheld to prevent the onset of
several neurodegenerative diseases, including a fatal form of
epilepsy.
